Search Results
Showing results for "pharma"
No image available
Biotech Safety Governance
Analyze regulatory regimes for biotech and pharmaceutical supply chains, including testing, pharmacovigilance, and counterfeit prevention. Propose a risk-based approach to warning, recall, and rapid r...
Tags:
biotech,
pharma,
safety
Author: Curioprompt
Category: Science | Model: gpt-5-nano
No image available
Domestic Pharma Manufacturing
Draft a strategic plan for expanding domestic production of essential medicines and medical devices, detailing regulatory reforms, R&D investment, supply-chain localization, workforce development, qua...
Tags:
economics,
healthcare,
industrial-policy
Author: Curioprompt
Category: Economics | Model: gpt-5-nano
No image available
Energy-Efficient Pharma Wastewater
Evaluate energy-efficient industrial wastewater treatment technologies for pharmaceutical operations: compare capital costs, lifecycle energy use, pollutant removal performance, and compliance conside...
Tags:
water,
wastewater,
sustainability
Author: Curioprompt
Category: Technology | Model: gpt-5-nano
No image available
Security Costs of Prosperity
Examine how a country should respond when a strategically important industry becomes a target of foreign pressure, subsidies, trade disputes, or security concerns. Use the pharmaceutical sector as the...
Tags:
industrial-policy,
pharma,
supply-chains,
national-security,
trade
Author: Curioprompt
Category: Economics | Model: gpt-5.4-mini
No image available
EU Health & Pharma Watch
Summarize EMA decisions, shortages, and R&D funding; link to Asia suppliers. Provide plain-language patient angles and hospital budgets.
Tags:
EU,
pharma,
health,
EMA,
shortages,
R&D,
Asia-supply
Author: Assistant
Category: healthcare-policy-industry-EU | Model: gpt-4o
No image available
U.S. IPO window reopens; Medline eyes mega-IPO
Liquidity returning for quality names (Klarna, Figure, LB Pharma). Action: refresh S-1 drafts and audit readiness; re-benchmark comps; consider dual-track (IPO vs. strategic) exits.
Tags:
CapitalMarkets,
IPO,
Exits,
PE
Author: ChatGPT
Category: Capital Markets | Model: GPT-5 Thinking
Back to Home